公开(公告)号：US09464072B2

公开(公告)日：2016-10-11

申请号：US14569203

申请日：2014-12-12

Applicant: AbbVie Inc.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Yixian Long ,  Jurgen Dinges ,  Karla Drescher ,  Peer Jacobson ,  Hwan-soo Jae ,  Ravi Kurukulasuriya ,  James T. Link ,  David J. Madar ,  Jyoti R. Patel ,  Marina A. Pliushchev ,  Jeffrey J. Rohde ,  Lynne E. Rueter ,  Qi Shuai ,  Bryan K. Sorensen ,  Jiahong Wang ,  Karsten M. Wicke ,  Martin Winn ,  Dariusz Wodka ,  Vince Yeh ,  Hong Yong

IPC: A61K31/451 ,  A61K31/4523 ,  A61K31/55 ,  C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract translation: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经变性，抑郁和精神分裂症，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。

公开(公告)号：US09290444B2

公开(公告)日：2016-03-22

申请号：US14226615

申请日：2014-03-26

Applicant: ABBVIE INC.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Steven Fung ,  Peer B. Jacobson ,  Lynne E. Rueter ,  Marina I. Strakhova ,  Jiahong Wang ,  Jyoti R. Patel ,  Qi Shuai ,  James T. Link ,  Jeffrey J. Rohde ,  Jurgen Dinges ,  Bryan K. Sorensen ,  Martin Winn ,  Hong Yong ,  Vince S. Yeh

IPC: C07C235/14 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4439 ,  C07C235/22 ,  C07C237/24 ,  C07C271/28 ,  C07C311/46 ,  C07D207/48 ,  C07D257/04 ,  C07D261/08 ,  C07D295/088 ,  C07D401/04

CPC classification number: C07C235/14 ,  A61K31/165 ,  A61K31/19 ,  A61K31/4439 ,  C07C235/22 ,  C07C237/24 ,  C07C271/28 ,  C07C311/46 ,  C07C2601/14 ,  C07C2601/18 ,  C07C2603/74 ,  C07D207/48 ,  C07D257/04 ,  C07D261/08 ,  C07D295/088 ,  C07D401/04

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

公开(公告)号：US20150265613A1

公开(公告)日：2015-09-24

申请号：US14671030

申请日：2015-03-27

Applicant: AbbVie Inc.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Steven Fung ,  Peer B. Jacobson ,  Lynne E. Rueter ,  Marina I. Strakhova ,  Jiahong Wang ,  Jeffrey J. Rohde ,  Qi Shuai ,  James T. Link ,  Jyoti R. Patel ,  Jurgen Dinges ,  Bryan K. Sorensen ,  Hong Yong ,  Vince S. Yeh ,  Ravi Kurukulasuriya

IPC: A61K31/498 ,  A61K31/165 ,  A61K31/4409 ,  A61K31/415 ,  A61K31/44 ,  A61K31/451 ,  A61K31/4015 ,  A61K31/196 ,  A61K31/381

CPC classification number: A61K31/498 ,  A61K31/165 ,  A61K31/195 ,  A61K31/196 ,  A61K31/381 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/45 ,  A61K31/451 ,  A61K31/5377 ,  C07C233/11 ,  C07C233/52 ,  C07C233/58 ,  C07C233/63 ,  C07C237/24 ,  C07C311/46 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2603/74 ,  C07D207/277 ,  C07D211/78 ,  C07D213/56 ,  C07D231/12 ,  C07D261/08 ,  C07D333/24

Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

公开(公告)号：US20150099740A1

公开(公告)日：2015-04-09

申请号：US14569203

申请日：2014-12-12

Applicant: AbbVie Inc.

Inventor： R. Scott Bitner ,  Kaitlin E. Browman ,  Michael E. Brune ,  Yixian Chen ,  Jurgen Dinges ,  Karla Drescher ,  Peer Jacobson ,  Hwan-soo Jae ,  Ravi Kurukulasuriya ,  James T. Link ,  David J. Madar ,  Jyoti R. Patel ,  Marina A. Pliushchev ,  Jeffrey J. Rohde ,  Lynne E. Rueter ,  Qi Shuai ,  Bryan K. Sorensen ,  Jiahong Wang ,  Karsten M. Wicke ,  Martin Winn ,  Dariusz Wodka ,  Vince Yeh ,  Hong Yong

IPC: C07D403/12 ,  C07D401/14 ,  C07D207/267 ,  C07D401/12

CPC classification number: C07D403/12 ,  A61K31/44 ,  A61K31/495 ,  C07D207/267 ,  C07D401/12 ,  C07D401/14

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract translation: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经退行性疾病，抑郁症和精神分裂症，包括向需要这种治疗的患者施用有效量的11-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。